StemCell Institute (TSE:7096) Net Income From Continuing Operations : 円311 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is StemCell Institute Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. StemCell Institute's net income from continuing operations for the three months ended in Sep. 2024 was 円0 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was 円311 Mil.

StemCell Institute Net Income From Continuing Operations Historical Data

The historical data trend for StemCell Institute's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemCell Institute Net Income From Continuing Operations Chart

StemCell Institute Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

382.53

91.45

212.55

278.96

441.33

StemCell Institute Quarterly Data
	Mar18	Mar19	Dec19	Mar20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
Net Income From Continuing Operations	Get a 7-Day Free Trial													75.69	84.11	95.19	56.00	-

StemCell Institute Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円311 Mil.

StemCell Institute Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemCell Institute (TSE:7096) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Shimbashi, Minato-ku, Tamuracho Building, Matsuoka, Tokyo, JPN, 105-0004

Website

https://www.stemcell.co.jp

StemCell Institute is engaged in Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's own cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood.

StemCell Institute Headlines

No Headlines